title: Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis.
abstract: Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities. We present the first reported case, to our knowledge, of immune-mediated nephritis following the administration of Tremelimumab (CP-675, 206), an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody. High-dose steroid therapy led to a rapid improvement in renal function, avoiding the need for renal replacement therapy.
authors.affiliation: Renal Unit , Lister Hospital , Coreys Mill Lane, Stevenage, Hertfordshire SG1 4AB.
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Jolly
authors.affiliation: Renal Unit , Addenbrooke's Hospital , Hills Road, Cambridge CB2 2QQ.
authors.forename: Menna R
authors.initials: MR
authors.lastname: Clatworthy
authors.affiliation: Renal Unit , Lister Hospital , Coreys Mill Lane, Stevenage, Hertfordshire SG1 4AB.
authors.forename: Christopher
authors.initials: C
authors.lastname: Lawrence
authors.affiliation: Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN , UK.
authors.forename: Paul D
authors.initials: PD
authors.lastname: Nathan
authors.affiliation: Renal Unit , Lister Hospital , Coreys Mill Lane, Stevenage, Hertfordshire SG1 4AB.
authors.forename: Ken
authors.initials: K
authors.lastname: Farrington
keywords: CTLA-4 antibody; acute renal impairment; interstitial nephritis